Mobile website
Characteristics in Biodistribution and Metabolism of 131 I Labeled Immunotoxin Against Human Bladder Carcinoma in Tumor-Bearing Nude Mice
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the possibility of radiolabelled immunotoxin BDI-1-MT used as bladder cancer guiding therapeutic agent, the biodistribution and metabolism of 131 I-BDI-1-MT in nude mice bearing human bladder carcinoma xenografts were studied.Methods:Monoclonal antibody BDI-1 was coupled with momordin (MT) by bifunctional agent SPDP. BDI-1 and BDI-1-MT were labeled with 131 I using ChT method. Nude mice with human bladder carcinoma BIU-87 xenografts were divided into two groups-131 I-BDI-1-MT group (10 mice) and 131 I-BDI-1 group (10 mice). In one mouse for each group, 629 MBq 131 I BDI-1-MT or 131 I BDI-1 was intravenously injected and γ imaging was performed 48 h, 72 h and 120 h postinjection. In other nine mice for each group, 0.74 MBq 131 I-BDI-1-MT or 131 I-BDI-1 was injected and biodistribution was measured at 48 h,72 h and 120 h postinjection respectively (3 mice at a time point ). The percent uptake dose per gram of tissues (%ID/g) and tumor over non-tumor radioactivity ratio (T/NT ) were calculated. Results:There was no significantly decrease in tumor uptake of 131 I-BDI-1-MT comparing with 131 I-BDI-1. The uptake of 131 I-BDI-1-MT in most of normal tissues was lower than that of 131 I-BDI-1, so T/NT values of 131 I-BDI-1-MT were higher than that of 131 I-BDI-1. The kidney uptake of131 I-BDI-1-MT was higher than that of 131 I-BDI-1. Tumor image could be seen 48 h postinjection for both 131 I-BDI-1-MT and 131 I-BDI-1 and got more clear with time lasted. But the image contrast of 131 I-BDI-1-MT was better than that of 131 I-BDI-1. There was no obvious difference in clearance rate of 131 I-BDI-1-MT and 131 I-BDI-1 in tumor. The clearance rate of 131 I-BDI-1-MT in normal tissues was significantly higher than that of 131 I-BDI-1 especially in blood. Conclusion: It demonstrated that 131 I-BDI-1-MT can effectively target to bladder cancer cells.
Keywords:
Project Supported:
Clc Number:
